Compare KBSX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | TNGX |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 1.4B |
| IPO Year | N/A | N/A |
| Metric | KBSX | TNGX |
|---|---|---|
| Price | $1.53 | $9.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 7.6K | ★ 2.6M |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $44,890,395.00 | ★ $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 30.46 | ★ 53.29 |
| 52 Week Low | $1.26 | $1.03 |
| 52 Week High | $15.48 | $11.20 |
| Indicator | KBSX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 52.39 |
| Support Level | $1.31 | $8.89 |
| Resistance Level | $1.60 | $10.22 |
| Average True Range (ATR) | 0.04 | 0.63 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 36.45 | 20.91 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.